Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LH 
Laboratory Corporation of America Holdings (LH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: LH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $277.23
1 Year Target Price $277.23
| 13 | Strong Buy |
| 3 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.85% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.12B USD | Price to earnings Ratio 30.48 | 1Y Target Price 277.23 |
Price to earnings Ratio 30.48 | 1Y Target Price 277.23 | ||
Volume (30-day avg) 20 | Beta 0.79 | 52 Weeks Range 196.61 - 265.72 | Updated Date 07/2/2025 |
52 Weeks Range 196.61 - 265.72 | Updated Date 07/2/2025 | ||
Dividends yield (FY) 1.10% | Basic EPS (TTM) 8.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.55% | Operating Margin (TTM) 9.94% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) 8.98% |
Valuation
Trailing PE 30.48 | Forward PE 16.47 | Enterprise Value 28268762000 | Price to Sales(TTM) 1.68 |
Enterprise Value 28268762000 | Price to Sales(TTM) 1.68 | ||
Enterprise Value to Revenue 2.15 | Enterprise Value to EBITDA 15.61 | Shares Outstanding 83700000 | Shares Floating 83247183 |
Shares Outstanding 83700000 | Shares Floating 83247183 | ||
Percent Insiders 0.36 | Percent Institutions 96.44 |
Analyst Ratings
Rating 4 | Target Price 277.23 | Buy 3 | Strong Buy 13 |
Buy 3 | Strong Buy 13 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Laboratory Corporation of America Holdings
Company Overview
History and Background
Laboratory Corporation of America Holdings (Labcorp) was formed in 1995 through the merger of Roche Biomedical Laboratories and National Health Laboratories. It has grown through acquisitions and organic growth to become one of the largest clinical laboratory networks globally.
Core Business Areas
- Diagnostics: Provides a broad range of routine and specialized clinical laboratory tests and services to healthcare providers, hospitals, managed care organizations, and pharmaceutical companies. Includes testing for infectious diseases, cancer, cardiovascular diseases, and other conditions.
- Drug Development: Offers drug development services to pharmaceutical and biotechnology companies, including clinical trial management, central laboratory services, and bioanalytical testing.
Leadership and Structure
Adam Schechter is the Chairman and CEO. The company operates with a corporate structure that includes various executive vice presidents overseeing different business segments and functions.
Top Products and Market Share
Key Offerings
- Routine Clinical Testing: Comprehensive suite of standard blood, urine, and other tests used for diagnosis and monitoring. Labcorp holds a significant share in this market. Competitors include Quest Diagnostics and smaller regional labs. Revenue difficult to isolate as part of broader diagnostics segment.
- Specialty Testing: Advanced diagnostic tests in areas such as genetics, oncology, and immunology. This is a high-growth area with strong demand. Competitors include NeoGenomics and Myriad Genetics. Revenue difficult to isolate as part of broader diagnostics segment.
- Drug Development Services: Clinical trial management and laboratory services for pharmaceutical companies. Labcorp is a major player in this market. Competitors include IQVIA and PPD. Revenue can be found on Labcorp's quarterly/annual reports.
Market Dynamics
Industry Overview
The clinical laboratory services industry is characterized by consolidation, technological advancements, and increasing demand for diagnostic testing. Factors driving growth include an aging population, rising prevalence of chronic diseases, and personalized medicine.
Positioning
Labcorp is a leading provider of clinical laboratory services, with a strong national presence and a comprehensive test menu. Its competitive advantages include its extensive network, scale, and expertise in specialized testing.
Total Addressable Market (TAM)
The global clinical laboratory services market is estimated to be worth over $250 billion. Labcorp is well-positioned to capture a significant share of this TAM through its diverse service offerings and strong market presence.
Upturn SWOT Analysis
Strengths
- Extensive laboratory network
- Comprehensive test menu
- Strong brand reputation
- Established relationships with healthcare providers
- Large scale and economies of scale
Weaknesses
- High debt levels
- Reliance on reimbursement rates
- Exposure to regulatory changes
- Competition from smaller, more specialized labs
- Past legal settlements related to billing practices
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Acquiring smaller labs
- Leveraging technology for efficiency improvements
- Partnering with pharmaceutical companies for drug development
Threats
- Decreasing reimbursement rates
- Increasing competition
- Technological disruptions
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- QDEL
- DGX
- HOLX
Competitive Landscape
Labcorp faces intense competition from Quest Diagnostics, as well as from smaller regional and specialized labs. Its advantages include its scale, comprehensive test menu, and strong brand reputation.
Major Acquisitions
Personal Genome Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 575
- Strategic Rationale: Expanding cancer genomic profiling capabilities.
Growth Trajectory and Initiatives
Historical Growth: Labcorp has experienced moderate growth over the past several years, driven by acquisitions and organic expansion.
Future Projections: Analyst estimates project continued growth, although the pace may be affected by economic conditions and regulatory changes.
Recent Initiatives: Recent initiatives include expanding its specialty testing capabilities, investing in technology, and pursuing strategic acquisitions.
Summary
Labcorp is a major player in the clinical laboratory services industry, characterized by a strong network and comprehensive test offerings. Decreasing reimbursement rates from payers may be a concern. The company is exposed to the risk of increasing debt levels. Future opportunities include expansion into emerging markets and partnerships with pharma companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Laboratory Corporation of America Holdings
Exchange NYSE | Headquaters Burlington, NC, United States | ||
IPO Launch date 1990-03-29 | President, CEO & Chairman Mr. Adam H. Schechter | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 60900 | Website https://www.labcorp.com |
Full time employees 60900 | Website https://www.labcorp.com | ||
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.